Maximum quantity allowed is 999
Please select the quantity
CAS RN: 211915-06-9 | Product Number: D5904
Dabigatran Etexilate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- Ethyl N-[[2-[[4-[N-[(Hexyloxy)carbonyl]carbamimidoyl]anilino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alaninate
- Ethyl 3-[2-[[[4-[N-[(Hexyloxy)carbonyl]carbamimidoyl]phenyl]amino]methyl]-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido]propanoate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 250MG |
NT$4,720
|
2 | 0 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | D5904 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__3__4H__4__1N__7O__5 = 627.75 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container | 250MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 211915-06-9 |
| Reaxys Registry Number | 10137269 |
| PubChem Substance ID | 468591633 |
| MDL Number | MFCD22422841 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 129.0 to 133.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 131 °C |
GHS
Related Laws:
Transport Information:
| H.S.code* | 2933.39-000 |
Application
Dabigatran Etexilate: An Oral, Reversible Direct Thrombin Inhibitor
Dabigatran etexilate is an oral, reversible direct thrombin inhibitor, and a prodrug of dabigatran [D5902]. Thrombin enables the conversion of fibrinogen into fibrin during the blood coagulation cascade. The inhibition prevents the development of a thrombus. Therefore, thrombin-induced platelet aggregation are inhibited by the active metabolite, dabigatran. In clinical, it is used as an alternative to warfarin [W0005] and does not require monitoring of blood coagulation parameters by blood tests. (The product is for research purpose only.)
References
- Advancement in antithrombotics for stroke prevention in atrial fibrillation (a review)
- Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.